
Quince Therapeutics Inc
NASDAQ:QNCX

Fundamental Analysis


Revenue & Expenses Breakdown
Quince Therapeutics Inc
Balance Sheet Decomposition
Quince Therapeutics Inc
Current Assets | 33.8m |
Cash & Short-Term Investments | 31.6m |
Other Current Assets | 2.2m |
Non-Current Assets | 73.3m |
Long-Term Investments | 78k |
PP&E | 941k |
Intangibles | 62.4m |
Other Non-Current Assets | 9.9m |
Free Cash Flow Analysis
Quince Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Quince Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-60.9m
USD
|
Operating Income
|
-60.9m
USD
|
Other Expenses
|
216k
USD
|
Net Income
|
-60.7m
USD
|
QNCX Profitability Score
Profitability Due Diligence
Quince Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Score
Quince Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
QNCX Solvency Score
Solvency Due Diligence
Quince Therapeutics Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.

Score
Quince Therapeutics Inc's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
QNCX Price Targets Summary
Quince Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
QNCX
is 7.4 USD
with a low forecast of 4.04 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for QNCX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?